Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and a leading cause of cancer-related death worldwide. Minimally invasive (MI) techniques, including robotic surgery, have emerged as promising alternatives to traditional open surgery for HCC resection. This review aims to provide a comprehensive overview of MI robotic techniques for HCC resection, discussing their advantages, disadvantages, and current clinical applications.
HCC is an aggressive malignancy with a poor prognosis, with an overall 5-year survival rate of less than 20%. Surgery is the only potentially curative treatment for HCC, and the extent of resection is a critical prognostic factor. However, traditional open hepatectomy is associated with significant morbidity and mortality, which can limit its applicability in certain patients.
MI techniques, such as laparoscopic and robotic surgery, have gained popularity in recent years due to their potential to offer several advantages over open surgery, including:
Reduced incision size and surgical trauma
Decreased postoperative pain and recovery time
Improved cosmetic outcomes
Shorter hospital stays
Robotic surgery, in particular, offers several advantages over laparoscopic surgery, including:
Enhanced surgeon dexterity and precision
Improved visualization of the surgical field
Greater range of motion of surgical instruments
Reduced ergonomic strain on the surgeon
As a result of these advantages, MI techniques have become increasingly popular for HCC resection. In fact, a recent meta-analysis of over 10,000 patients undergoing HCC resection found that MI techniques were associated with significantly reduced postoperative pain, hospital stay, and wound complications compared to open surgery.
The use of MI robotic techniques for HCC resection offers several potential advantages over traditional open surgery, including:
Improved oncologic outcomes: Studies have shown that MI robotic techniques are associated with comparable oncologic outcomes to open surgery, with equivalent survival rates and recurrence rates.
Reduced morbidity: MI robotic techniques are associated with significantly reduced postoperative pain, hospital stay, and wound complications compared to open surgery.
Improved quality of life: Patients who undergo MI robotic HCC resection often experience a faster return to normal activities and an improved quality of life compared to patients who undergo open surgery.
Despite the many advantages of MI robotic techniques for HCC resection, there are also some potential disadvantages, including:
Longer operative time: MI robotic procedures may take slightly longer than open surgery due to the increased complexity of the procedure.
Steeper learning curve: Surgeons require extensive training to become proficient in MI robotic techniques.
Higher cost: The cost of MI robotic equipment and instrumentation is higher than the cost of traditional laparoscopic equipment.
Anatomical liver resection: This type of resection involves removing the entire tumor and a margin of healthy liver tissue.
Laparoscopic segmentectomy: This type of resection involves removing a single segment of the liver.
Radiofrequency ablation (RFA): This type of treatment involves using radiofrequency waves to destroy the tumor.
MI robotic techniques have emerged as promising alternatives to traditional open surgery for HCC resection. These techniques offer several potential advantages, including reduced morbidity, improved quality of life, and comparable oncologic outcomes. With continued advances in technology and training, MI robotic techniques are likely to play an increasingly important role in the treatment of HCC.
The future of MI robotic techniques for HCC resection is bright. With continued advances in technology and training, these techniques are likely to become even more widely adopted. Additionally, new robotic platforms are being developed that offer even greater dexterity and precision, which could further improve the outcomes of MI robotic HCC resection.
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation